Convalescent Plasma: An Evidence-Based Old Therapy to Treat Novel Coronavirus Patients

Saurabh Kumar, Chandra Devi, Subhabrata Sarkar, Vivek Kumar Garg, Priyanka Choudhary, Madhu Chopra, Vinit Sharma and Ravi Prakash

A chapter in Biotechnology to Combat COVID-19 from IntechOpen

Abstract: Novel Coronavirus (nCoV-2019) is a highly infectious viral outbreak that has so far infected more than 110 million people worldwide. Fast viral transmission and high infection rates have severely affected the entire population, especially the old aged and comorbid individuals leaving significantly less time to find some effective treatment strategy. In these challenging times, convalescent plasma (CP) therapy came as a ray of hope to save humankind. It is a form of passive immunization that has been used to treat various infectious diseases since 1890, including the 1918 Spanish flu, 2002/03 SARS-CoV, 2009 H1N1, 2012 MERS-CoV, and 2014 Ebola outbreak. The transfusion includes administration of CP containing a high value of neutralizing antibodies against the virus in hospitalized patients. This chapter summarizes the potential outcome of CP therapy in the treatment of nCoV-2019 patients.

Keywords: nCoV-2019; CP therapy; viral infection; neutralizing antibody (search for similar items in EconPapers)
JEL-codes: I18 (search for similar items in EconPapers)
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.intechopen.com/chapters/76142 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ito:pchaps:231763

DOI: 10.5772/intechopen.97073

Access Statistics for this chapter

More chapters in Chapters from IntechOpen
Bibliographic data for series maintained by Slobodan Momcilovic ().